We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned an average recommendation of “Moderate ...

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, were published as an original research ...

BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the market ...

Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for BridgeBio Pharma in a report released ...

One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company focused on developing transformative medicines for patients with genetic diseases and cancers. Its primary ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by Scotiabank from $44.00 to $45.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a ...